Biocon is fully integrating Biocon Biologics, valuing its biosimilar business at $5.5 billion. This move removes debt concerns and improves financial health. The combined entity will leverage synergies across manufacturing, R&D, and commercial operations. This integration aims to accelerate launches in major markets and unlock significant growth opportunities for the unified global player.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/rvdhy2q
via IFTTT
No comments:
Post a Comment